In a recent assessment by the Central Drugs Standard Control Organization (CDSCO), one of India's top regulatory bodies, over 50 drugs failed quality control tests, sparking concerns about the safety and efficacy of several medications. The report includes widely used drugs, such as Paracetamol, along with a variety of antibiotics, vitamin supplements, and medications for chronic conditions like high blood pressure and diabetes.
Among the 53 drugs tested, 48 failed the quality tests. Notably, medications produced by prominent pharmaceutical companies such as Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), and Karnataka Antibiotics and Pharmaceuticals Limited were found to be substandard.
The list of failed drugs includes essential medications such as:
Of particular concern, Metronidazole, an antibiotic widely used to treat stomach infections, failed the test. This drug, manufactured by Hindustan Antibiotics Limited, is frequently prescribed for common gastrointestinal infections. Similarly, Shelcal Tablets, produced by Torrent Pharmaceuticals, also did not meet quality standards.
While 53 drugs were tested, only 48 were included in the final report because five of the failed drugs were found to be counterfeit. Manufacturers of these drugs claimed that the substandard medications were fake versions of their products, distributed illegally under their brand names. This raises further concerns about the proliferation of counterfeit drugs in the market, which can endanger patients' health.
Click Here to sell full list of Drugs
The recent CDSCO report follows a significant government crackdown on Fixed-Dose Combination (FDC) drugs in August. The government banned 156 FDC drugs, which are combinations of two or more active ingredients in a single tablet. These drugs, commonly used to treat conditions like fever, cold, pain, and infections, were found to pose potential risks to human health.
The Drug Technical Advisory Board (DTAB) concluded that many of the ingredients in FDC drugs had no medical justification for being combined. As a result, the government prohibited the production, consumption, and distribution of these medications across India.
In addition to the commonly prescribed medications, the government banned a range of drugs used for hair treatment, skincare, and anti-allergy treatments. Enzymes like Amylase, Protease, and Bromelain, which are used in various healthcare products, were found to potentially pose risks to human health.
While these medications have been banned, the government assured the public that alternatives are available in the market. These safer alternatives can be used without posing significant risks to patients.
This latest drug failure report mirrors earlier concerns raised in Rajasthan, where 10 drugs under the state’s Chief Minister's Free Medicine Scheme failed quality tests. These medications, supplied by eight different companies, included antifungal tablets, injections for severe malaria, eye drops, and asthma medications. The Rajasthan Medical Services Corporation (RMSC) halted the supply of these drugs after the failures came to light in May of this year.
The failure of such a large number of drugs in quality tests, including vital medications like Paracetamol, highlights significant concerns regarding drug manufacturing standards in India. With the country's reliance on affordable and accessible medication, particularly for chronic conditions like diabetes, hypertension, and infections, the findings of the CDSCO report emphasize the need for stricter regulatory oversight.
In response to the report, health experts are calling for increased vigilance in the manufacturing, distribution, and testing of medications. Patients are advised to consult with healthcare professionals regarding the safety of their prescriptions and to avoid buying medications from unverified or untrusted sources.
The government’s actions, including the ban on FDC drugs and continuous quality checks, aim to protect public health and ensure that the medications available in the Indian market are safe and effective.
The CDSCO's findings serve as a critical reminder of the importance of rigorous quality control in the pharmaceutical industry. With over 50 drugs failing to meet quality standards, the Indian government has taken decisive action to address the issue, but much work remains to be done to protect patients from substandard and counterfeit medications.
Via: (Source)
Comments